Replies to post #152669 on Cytodyn Inc (CYDY)

[All-Bidness]

I think there is some middle ground here. We did not meet primary endpoint, however there the secondary endpoints showed that this drug is better than any other therapeutic that has been approved to date. That in itself has value.

[Dieselpro]

But keep in mind CD12 trial is not even at the 1 year mark yet. Trials typically take 5 to 7 years. The reason for this is searching for what works. Now that positive data has come from the trial they have a path to approval in a matter of months. That is still extremely fast and unheard of. Is it fast enough for get rich quick investors and day traders, no, but CYDY will pay off big when approval comes.

And not only did they design, fill and complete the trial in less than a year, they did two trials CD10 and CD12. Both trials producing very valuable positive data. This is still at the beginning and is looking very promising for an approval for covid-19. The big revenue won't come from selling Leronlimab to treat covid it will come from all other ARDS illnesses. Covid will just serve as an open door.

[moneycrew]

BUT better than any other drug out there, wait until the FDA takes another look at Leronlimab, I'll bet you'll see a PR with a picture of an approved stamp on a cover letter.